Top 10 Healthcare Market Research Companies Using Real-World Evidence

 Real-world evidence (RWE) has rapidly evolved into a critical foundation for modern healthcare decision-making. As global healthcare systems shift toward value-based care, life sciences organizations, payers, and regulatory authorities increasingly rely on real-world data (RWD) sources—including electronic health records, claims datasets, patient registries, genomics data, and patient-reported outcomes—to validate clinical assumptions and understand treatment performance outside controlled trial environments. RWE not only supports refined clinical development strategies but also plays a core role in market access, regulatory approval, post-market surveillance, and health economics outcomes research (HEOR).

Pharmaceutical companies today require market research partners capable of generating high-quality real-world evidence to demonstrate therapeutic value, drive pricing and reimbursement strategies, and optimize launch success. The following list highlights the top 10 healthcare market research companies leading the RWE landscape worldwide and shaping the future of evidence-based healthcare innovation.

IQVIA

IQVIA stands as the global benchmark for real-world evidence generation in healthcare research. With unmatched access to one of the world’s most extensive RWD networks—representing more than one billion patient-level records—the company enables evidence-driven decisions across drug development, commercialization, and market access. IQVIA’s capabilities span real-world clinical trials, retrospective and prospective observational research, comparative effectiveness evaluation, HEOR, predictive analytics, and patient outcome modeling. Its data science platforms use advanced machine learning and AI to accelerate study execution and integrate outcomes insights into regulatory submissions and payer communications. IQVIA’s influence extends across therapeutic categories, including oncology, immunology, and rare diseases, making it a preferred partner for top global pharmaceutical developers.

Syneos Health

Syneos Health integrates clinical development, commercialization strategy, and data-driven evidence services into a unified framework, enabling clients to align research and commercial planning. The organization leverages real-world data from large population databases and payer-level analytics to support product value demonstration and market access strategy. Syneos Health is particularly known for patient-focused RWE research, advanced outcomes modeling, and specialized capabilities in specialty therapies and rare diseases. Its approach helps organizations engage stakeholders more effectively and deliver credible evidence that supports reimbursement negotiations, policy planning, and lifecycle management initiatives.

McKinsey & Company

McKinsey & Company has built a strong presence in the real-world evidence arena through strategic acquisitions and the expansion of its healthcare analytics practice. The firm advises government health agencies, providers, pharmaceutical innovators, and investors on how to leverage RWE to strengthen clinical effectiveness insights, increase treatment accessibility, and optimize healthcare system value. McKinsey’s support spans therapeutic landscape evaluation, portfolio prioritization, health economic modeling, and payer strategy. By combining world-leading strategic consulting with large-scale data modeling, McKinsey helps clients design actionable frameworks around real-world outcomes and future-of-health transformation.

DelveInsight

DelveInsight is a specialized healthcare market research and consulting firm known for deep therapeutic expertise and evidence-based strategic insights. The company delivers real-world evidence analytics across epidemiology research, HEOR, patient journey assessment, and clinical and commercial forecasting. DelveInsight supports emerging and established biopharmaceutical and med-tech companies with structured real-world intelligence that guides investment and clinical development decisions. Its focus on rare diseases, oncology, immunology, neurology, and cell and gene therapy markets makes it especially valuable for companies working with complex and high-unmet-need therapeutic areas. With comprehensive disease-specific datasets and real-world outcomes insights, DelveInsight plays a critical role in shaping strategy for drug developers preparing for launch, planning market expansion, or evaluating competitive pipelines.

Clarivate

Clarivate provides scientific intelligence and real-world evidence capabilities through integrated research, analytics, and global patient data. Through platforms such as Cortellis, the company supports commercial planning, clinical positioning, evidence generation, and lifecycle management. Clarivate’s workflows enable cross-functional alignment among R&D, regulatory affairs, commercial teams, and medical affairs. Specializing in precision medicine, digital data integration, bibliometrics, and market forecasting, Clarivate helps clients validate treatment demand and understand clinical and competitive dynamics through real-world insights. Its evidence frameworks are widely used to strengthen reimbursement documentation and improve asset valuation for investors and strategic partners.

Optum

Optum offers one of the largest and most detailed healthcare claims and EHR repositories in the United States, enabling comprehensive real-world evidence research for biopharma, health plans, and academic institutions. The company supports retrospective studies, longitudinal treatment evaluation, cost-effectiveness modeling, population health insights, and real-world clinical performance analysis. Optum’s multidisciplinary approach integrates clinical research expertise with advanced analytics and health system knowledge, helping organizations improve value-based care initiatives and treatment pathway strategies. Optum is also a leader in real-world evidence applications related to healthcare cost reduction, payer contracting, and outcomes-driven care delivery.

Kantar Health (Evidera division of PPD/Thermo Fisher Scientific)

Kantar Health is recognized for its expertise in patient-centered real-world insights, HEOR research, and global outcomes measurement. The organization delivers patient-reported outcomes, quality-of-life studies, burden of illness assessments, and real-world treatment experience evaluations across therapeutic specialties. With sophisticated behavioral science and analytics methodologies, Kantar Health helps clients understand real-world decision dynamics influencing treatment adoption, adherence, and patient satisfaction. Its evidence supports product positioning, regulatory dossier development, pricing evaluation, and launch planning across multiple markets.

Precision Xtract

Precision Xtract is highly regarded for its expertise in market access, HEOR, and cost-effectiveness research supported by robust real-world evidence methodologies. The company focuses on real-world value demonstration for specialty and rare disease products, high-cost innovative therapies, and complex biologics. Services include health economics modeling, value dossier development, real-world comparative effectiveness studies, and payer evidence strategy. Precision Xtract’s work supports reimbursement strategy and helps companies communicate therapeutic value to decision-makers such as payers, health systems, and HTA bodies.

ICON

ICON provides real-world evidence capabilities spanning patient registries, noninterventional research, claims database studies, and digital data collection. The company conducts RWE studies to support post-authorization safety requirements, comparative effectiveness assessments, and patient journey mapping. ICON’s analytics platforms allow pharmaceutical companies to evaluate real-world clinical outcomes, safety signals, and market dynamics more accurately. ICON is known for combining clinical expertise with advanced data tools to support regulatory submissions, market access strategy, and lifecycle management across medical devices, biologics, and pharmaceuticals.

WNS Trianz

WNS Trianz delivers end-to-end healthcare analytics, AI-driven modeling, and RWD integration designed to support data transformation and RWE strategy. The company works with biopharma, payers, and providers to create predictive analytics frameworks, operational performance insights, and clinical outcome evaluation models. WNS Trianz specializes in digital transformation across the healthcare continuum, using real-world data to improve care pathway optimization, patient segmentation, and strategic forecasting. Its technology-enabled approach positions it as an innovative partner for organizations seeking to modernize research and evidence-based decision infrastructure.

The Growing Importance of Real-World Evidence in Healthcare

Real-world evidence is rapidly becoming a keystone for healthcare evaluation and policy as regulatory agencies such as the U.S. FDA and European EMA encourage its use to support regulatory approvals and complement clinical trial evidence. Payers increasingly demand RWE to substantiate reimbursement and pricing decisions, while physicians and providers use insights to optimize treatment pathways and enhance clinical outcomes. Investors also regard RWE as a critical indicator of commercial success potential.

The future of RWE will be shaped by advancements in digital health, remote monitoring, genomics-enabled personalized therapy, and artificial intelligence capable of analyzing large-scale health datasets in real time. Companies that successfully integrate data science with medical expertise and strategic research capabilities will define the next chapter of evidence-based healthcare transformation.

Organizations leading this space are not just interpreting clinical insights—they are reshaping the industry by equipping healthcare stakeholders with stronger evidence, clearer value demonstration, and deeper understanding of real-world patient care performance.